Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

2018 ◽  
Vol 107 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Juha‐Pekka Mattila ◽  
Leonardo Mirandola ◽  
Maurizio Chiriva‐Internati
Keyword(s):  
Ovarian Cancer ◽  
Oral Immunization ◽  
M Cell ◽  
Cancer Antigen ◽  
Sperm Protein ◽  
Sperm Protein 17

Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine

Vaccine ◽  
2015 ◽  
Vol 33 (44) ◽  
pp. 5950-5959 ◽  
Author(s):  
Sue D. Xiang ◽  
Qian Gao ◽  
Kirsty L. Wilson ◽  
Arne Heyerick ◽  
Magdalena Plebanski
Keyword(s):  
Ovarian Cancer ◽  
B Cell ◽  
Cancer Vaccine ◽  
B Cell Epitopes ◽  
Sperm Protein ◽  
Sperm Protein 17

Sperm Protein 17 is a Suitable Target for Adoptive T-cell–based Immunotherapy in Human Ovarian Cancer

2008 ◽  
Vol 31 (8) ◽  
pp. 693-703 ◽  
Author(s):  
Maurizio Chiriva-Internati ◽  
Jon A. Weidanz ◽  
Yuefei Yu ◽  
Eldo E. Frezza ◽  
Marjorie R. Jenkins ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cell ◽  
Human Ovarian Cancer ◽  
Sperm Protein ◽  
Suitable Target ◽  
Sperm Protein 17

scholarly journals Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression

Cancers ◽  
2018 ◽  
Vol 10 (8) ◽  
pp. 276 ◽  
Author(s):  
Qian Gao ◽  
Sue Xiang ◽  
Kirsty Wilson ◽  
Mutsa Madondo ◽  
Andrew Stephens ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Tumor Progression ◽  
Vaccine Development ◽  
Ovarian Cancer Cells ◽  
Sperm Protein ◽  
Mhc Ii ◽  
Sperm Protein 17

The cancer testis antigen sperm protein 17 (Sp17) is a promising antigenic target in epithelial ovarian cancer (EOC) vaccine development. However, its role in ovarian cancer is unclear. We isolated and expanded Sp17+ and Sp17− clones from the murine EOC cell line ID8, and compared their in-vitro cell growth characteristics and in-vivo tumorigenicity. We also examined the potential co-expression of molecules that may influence cancer cell survival and interaction with immune cells. These include stimulatory and immunosuppressive molecules, such as major histocompatibility class I molecules (MHC I), MHC II, cytotoxic T lymphocyte associated antigen-4 (CTLA-4), CD73, CD39, tumor necrosis factor receptor II (TNFRII), signal transducer and activator of transcription 3 (STAT3) and programmed death-ligand 1 (PD-L1). Whilst the presence of Sp17 was not correlated with the ID8 cell proliferation/growth capacity in vitro, it was critical to enable progressive tumor formation in vivo. Flow cytometry revealed that Sp17+ ID8 cells displayed higher expression of both STAT3 and PD-L1, whilst MHC II expression was lower. Moreover, Sp17high (PD-L1+MHCII−) cell populations showed significantly enhanced resistance to Paclitaxel-induced cell death in vitro compared to Sp17low (PD-L1−MHCII+) cells, which was associated in turn with increased STAT3 expression. Together, the data support Sp17 as a factor associated with in-vivo tumor progression and chemo-resistance, validating it as a suitable target for vaccine development.

scholarly journals Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Laurie L. Brunette ◽  
Paulette Y. Mhawech-Fauceglia ◽  
Lingyun Ji ◽  
Joseph G. Skeate ◽  
Heike E. Brand ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Retrospective Study ◽  
Epithelial Ovarian Cancer ◽  
Prognostic Significance ◽  
Tumor Biomarker ◽  
Sperm Protein ◽  
Sperm Protein 17

scholarly journals Expression of sperm protein 17 (Sp17) in ovarian cancer

2004 ◽  
Vol 108 (6) ◽  
pp. 805-811 ◽  
Author(s):  
J. Michael Straughn ◽  
Denise R. Shaw ◽  
Antonio Guerrero ◽  
Snehal M. Bhoola ◽  
Alicia Racelis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Sperm Protein ◽  
Sperm Protein 17

Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer

2007 ◽  
Vol 17 (2) ◽  
pp. 426-432 ◽  
Author(s):  
T. Nakazato ◽  
T. Kanuma ◽  
T. Tamura ◽  
L. S. Faried ◽  
H. Aoki ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Carcinoma ◽  
Differential Expression ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Clear Cell Adenocarcinoma ◽  
Serous Adenocarcinoma ◽  
Sperm Protein ◽  
Adenocarcinoma Of The Ovary ◽  
Sperm Protein 17

Clear cell adenocarcinoma of the ovary has a poor prognosis due to chemoresistance and early metastasis to the lymph nodes. It also can result in endometriosis and is the second most frequent type of ovarian cancer in Japan. Serous adenocarcinoma of the ovary is another common epithelial cancer tissue subtype in Japan, and it is highly sensitive to chemotherapy. In the current study, we examined the differential expression of genes in these types of ovarian cancer and tried to analyze their functions, especially as they relate to chemoresistance. We used differential display to compare clear cell carcinoma and serous adenocarcinoma of the ovary. We identified sperm protein 17 (SP17) as a candidate gene related to the chemoresistance of clear cell carcinoma. Its differential expression was confirmed by real-time polymerase chain reaction. Because the function of the SP17 gene in ovarian cancer is not known, we examined the effect of small interfering RNA targeting the SP17 gene on the chemoresistance and proliferation of ES-2 ovarian cancer cells to paclitaxel, currently the most effective treatment for ovarian cancer. We found that this treatment decreased the chemoresistance of these cells to paclitaxel. Our results strongly suggest that SP17 plays a role in the resistance of clear cell carcinoma to chemotherapy without influencing their ability to proliferate

Sign in / Sign up

Export Citation Format

Share Document